glp 1 and basal insulin Frontiers Role of Glucagon-Like Peptide-1 (GLP-1)

You chose the drug over discipline

CagriSema is a fixed-dose combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist), and is currently an experimental obesity drug developed by Novo Nordisk

Obesity and type 2 diabetes remain critical global health challenges, with rising prevalence demanding innovative treatment approaches

Can you take Wegovy without a gallbladder

Results Cholelithiasis significantly associates GLP1-RAs (p=0.033)

For users this could segway into an expansion of the private market and for payers this could provide an affordable entry point for public reimbursement